London,UK, 2nd Mar 2026   Prime.io, a cell line engineering services company that uses automated AI-designed gene editing technology to deliver fast, high-quality gene knock-in (KI) and knock-out (KO) services to drug discovery clients, today announced the appointment of Sir Tony Kouzarides as Scientific Advisor. Bringing significant industry expertise and leadership, Sir Tony will provide strategic guidance to advance Prime.io’s next-generation gene editing services. He will also help foster new industry partnerships and broaden awareness of the Company’s long-term mission to edit genes and accelerate drug discovery. 

​

​In his role as Scientific Advisor, Tony will help shape the Company’s scientific strategy, identifying and advising on research and industry opportunities and raising awareness of Prime.io’s unique approach to cell line engineering. ​Tony is an esteemed academic and entrepreneur well known for his major role in the success of the Cambridge life sciences ecosystem, including co-founding both the Milner Therapeutics Institute and Abcam. Tony has significant experience in founding and growing therapeutics companies, including as co-founder and ex-director of Chroma Therapeutics, co-founder and director of STORM Therapeutics, and co-founder and CEO of Vellos. In addition to these roles, Tony is a Venture Partner at Fifty Years. 

​

Dr Rex Li, Founder and CEO, Prime.io, said- 

​​

“I’m extremely pleased to welcome Sir Tony Kouzarides to Prime.io. Tony is a highly renowned leader in healthcare and life sciences, and his career and achievements speak for themselves. We are incredibly grateful for his support of our mission — to edit genes and accelerate drug discovery — and I look forward to leveraging his experience to help propel the Company forward in pursuit of this goal.”  

​​​

​

​

Sir Tony Kouzaridies, Scientific Advisor, Prime.io, said-  

​

Prime.io is advancing a highly differentiated approach to cell line engineering, leveraging its AI-designed CRISPR technology to deliver superior knock-in and knock-out efficiency, reduced off-target activity, and faster project turnaround for oncology and drug discovery research. By combining a strong molecular biology foundation with automation capabilities and a client-centric commercial model, the company is positioning itself as a next-generation partner in drug discovery.

I am delighted to be joining Prime.io as a Scientific Advisor at this important stage of growth and look forward to working closely with Rex and the broader leadership team.

​​

​